Peapod Lane Capital LLC Purchases New Shares in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

Peapod Lane Capital LLC acquired a new position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 445,744 shares of the company’s stock, valued at approximately $673,000.

A number of other institutional investors and hedge funds have also made changes to their positions in PMVP. Virtu Financial LLC bought a new position in shares of PMV Pharmaceuticals in the 3rd quarter valued at about $42,000. Cubist Systematic Strategies LLC increased its stake in PMV Pharmaceuticals by 570.8% during the second quarter. Cubist Systematic Strategies LLC now owns 69,867 shares of the company’s stock worth $113,000 after acquiring an additional 59,452 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in PMV Pharmaceuticals by 36.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 353,837 shares of the company’s stock valued at $527,000 after buying an additional 93,809 shares during the period. M&T Bank Corp raised its stake in shares of PMV Pharmaceuticals by 54.6% in the third quarter. M&T Bank Corp now owns 399,548 shares of the company’s stock valued at $596,000 after acquiring an additional 141,064 shares during the period. Finally, BML Capital Management LLC lifted its holdings in shares of PMV Pharmaceuticals by 29.0% in the 3rd quarter. BML Capital Management LLC now owns 1,688,772 shares of the company’s stock worth $2,516,000 after acquiring an additional 379,375 shares during the last quarter. 90.20% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Oppenheimer upgraded shares of PMV Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a report on Friday, November 8th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $5.50.

PMV Pharmaceuticals Price Performance

Shares of PMVP stock opened at $1.36 on Thursday. The stock has a 50 day moving average price of $1.47 and a 200 day moving average price of $1.53. PMV Pharmaceuticals, Inc. has a 52-week low of $1.32 and a 52-week high of $2.26.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.